http://www.biomedpress.org/ Home News Journals Books Services About Us
Skip to main content Skip to main navigation menu Skip to site footer

 Letter to Editor

HTML

76

Total

4

Share

Expanded mesenchymal stem cell transplantation is safe in both local injection and vein transfusion






 Open Access   

Abstract

More than 500 clinical trials are using mesenchymal stem cells (MSCs) in the world to treat some different diseases. The safety of expanded MSC transplantation is the most important thing to ensure that this therapy can become the routine treatment of human illnesses. More than five MSCs based stem cell drug products are approved in various countries demonstrated that expanded MSCs are safe in both local injection and transfusion. Moreover, some recent reports for six years followed-up clinical trials using expanded MSCs confirmed that there is not different tumorigenesis between the patients with and without expanded MSC transplantation. This letter aims to provide some evidence about the safety of expanded MSCs in clinical applications. However, the MSC quality should be strictly controlled during the in vitro MSC expansion.

Abstract

More than 500 clinical trials are using mesenchymal stem cells (MSCs) in the world to treat some different diseases. The safety of expanded MSC transplantation is the most important thing to ensure that this therapy can become the routine treatment of human illnesses. More than five MSCs based stem cell drug products are approved in various countries demonstrated that expanded MSCs are safe in both local injection and transfusion. Moreover, some recent reports for six years followed-up clinical trials using expanded MSCs confirmed that there is not different tumorigenesis between the patients with and without expanded MSC transplantation. This letter aims to provide some evidence about the safety of expanded MSCs in clinical applications. However, the MSC quality should be strictly controlled during the in vitro MSC expansion.

1. Dear Editor-in-Chief

In 2017, more than ten publications used expanded to treat some diseases in both local injection and infusion in Pubmed [ 1–10 ]. All publications showed expanded MSC transplantation was safe. Some studies followed-up 12 months, others followed up to 6 years. And some transplantations are autologous, and others are allogeneic. In the recent report, Bartolucci et al. (2017) infused allogenic expanded MSCs from umbilical cord tissue at the dose of 1 106 cells/kg to treat heart failure and follow-up to 12 months [ 1 ]. At 12th months, only UC-MSC treated group significantly improved the left ventricular ejection fraction. More importantly, there were no differences in mortality, heart failure admissions, arrhythmias, or incident malignancy between treatment group and placebo group [ 1 ]. In another study, Pang et al. (2017) reported the results of the clinical trial using the allogenic expanded MSCs from bone marrow for aplastic anemia treatment [ 8 ]. After the median follow-up of 17 months, the overall survival was 87.8%; there were 7/74 patients developed a mild headache and fever, no other side effects were detected. With these results, authors confirmed that allogenic BM-derived MSCs are safe in aplastic anemia [ 8 ].

In India, a four year-follow up study used autologous expanded MSC from bone marrow to treat chronic stroke [ 9 ]. In this study, 12 chronic stroke patients were intravenously infused with autologous expanded MSCs. All patients were followed up the 208th week without any cell related side effects [ 9 ].

For local injection, two clinical trials using expanded MSCs with one clinical trial followed up six years were reported. Centeno et al. (2017) lumbar degenerative disc disease-associated radicular pain with autologous expanded MSCs. In this study, thirty-three patients injected with their expanded MSCs and followed up to 6 years post-treatment. There was no any severe side effect such as death, infection, and tumor in the patients related to MSC transplantation. Particularly, up to 85% patients had a reduction in disc bulge size with average reduction size of 23% post-treatment [ 2 ].

I also found another report about safety and efficacy of Cx601 products in the treatment of complex perianal fistulas in Crohn’s disease [ 3 ]. This study was funded by TiGenix to investigate the effectiveness of Cx601 – a stem cell drug containing allogenic adipose tissue-derived stem cells. The patients would be intralesionally injected with 120 million of Cx601 cells with the single injection. Patients were followed up to 52 weeks post-treatment. The results showed that 17% of patients treated with Cx601 and 29% patients in the placebo group had side effects included anal abscess and proctalgia [ 3 ].

By these reports, I initially concluded that autologous and allogenic expanded MSC transplantations are safe in both local injection and vein transfusion. However, more studies with longer time follow-up are essential to perform the meta-analysis review about the safety of expanded MSC transplantation.

2. Open Access

This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

3. List of abbreviations

BM: Bone marrow; MSCs: Mesenchymal stem cells; UC: Umbilical cord

4. Ethics approval and consent to participate

Not to be applied

5. Competing interests

The authors declare that no competing interests exist.

6. Funding

Not to be applied

7. Authors contributions

Both authors equally contributed in this manuscript, from preparing idea, looking references and writing. All authors approved the final manuscript.

8. Acknowledgements

Not to be applied

References

  1. Bartolucci Jorge, Verdugo FernandoJ, González PazL, Larrea RicardoE, Abarzua Ema, Goset Carlos, Rojo Pamela, Palma Ivan, Lamich Ruben, Pedreros PabloA, Valdivia Gloria, Lopez ValentinaM, Nazzal Carolina, Alcayaga-Miranda Francisca, Cuenca Jimena, Brobeck MatthewJ, Patel AmitN, Figueroa FernandoE, Khoury Maroun. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart FailureNovelty and Significance. Circulation Research. 2017-sep;:1192-1204. View Article PubMed Google Scholar
  2. Centeno Christopher, Markle Jason, Dodson Ehren, Stemper Ian, Williams ChristopherJ, Hyzy Matthew, Ichim Thomas, Freeman Michael. Treatment of lumbar degenerative disc disease-associated radicular pain with culture-expanded autologous mesenchymal stem cells: a pilot study on safety and efficacy. Journal of Translational Medicine. 2017-sep;:. View Article PubMed Google Scholar
  3. Panés Julián, García-Olmo Damián, Assche GertVan, Colombel JeanFrederic, Reinisch Walter, Baumgart DanielC, Dignass Axel, Nachury Maria, Ferrante Marc, Kazemi-Shirazi Lili, Grimaud JeanC, Portilla Fernandodela, Goldin Eran, Richard MariePaule, Leselbaum Anne, Danese Silvio. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn\textquotesingles disease: a phase 3 randomised, double-blind controlled trial. The Lancet. 2016-sep;:1281-1290. View Article Google Scholar
  4. Mehta RohteshS, Saliba RimaM, Cao Kai, Kaur Indreshpal, Rezvani Katy, Chen Julianne, Olson Amanda, Parmar Simrit, Shah Nina, Marin David, Alousi Amin, Hosing Chitra, Popat Uday, Kebriaei Partow, Champlin Richard, Lima Marcosde, Skerrett Donna, Burke Elizabeth, Shpall ElizabethJ, Oran Betul. Ex Vivo Mesenchymal Precursor Cell–Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biology of Blood and Marrow Transplantation. 2017-aug;:1359-1366. View Article Google Scholar
  5. Cohen JeffreyA, Imrey PeterB, Planchon SarahM, Bermel RobertA, Fisher Elizabeth, Fox RobertJ, Bar-Or Amit, Sharp SusanL, Skaramagas ThomaiT, Jagodnik Patricia, Karafa Matt, Morrison Shannon, Koc JaneReese, Gerson StantonL, Lazarus HillardM. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Multiple Sclerosis Journal. 2017-apr;:501-511. View Article Google Scholar
  6. Syková Eva, Rychmach Petr, Drahorádová Ivana, Konrádová ŠImona, R\ru\vzičková KateŖina, VoŖíšek Ivan, Forostyak Serhiy, Homola Aleš, Bojar Martin. Transplantation of Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: Results of Phase I/IIa Clinical Trial. Cell Transplantation. 2017-apr;:647-658. View Article Google Scholar
  7. Kastrup Jens, Haack-Sørensen Mandana, Juhl Morten, Søndergaard RebekkaHarary, Follin Bjarke, Lund LisbethDrozd, Johansen EllenMønsted, Qayyum AbbasAli, Mathiasen AndersBruun, Jørgensen Erik, Helqvist Steffen, Elberg JensJørgen, Bruunsgaard Helle, Ekblond Annette. Cryopreserved Off-the-Shelf Allogeneic Adipose-Derived Stromal Cells for Therapy in Patients with Ischemic Heart Disease and Heart Failure-A Safety Study. STEM CELLS Translational Medicine. 2017-sep;:1963-1971. View Article Google Scholar
  8. Pang Yan, Xiao Hao-Wen, Zhang Hang, Liu Zeng-Hui, Li Li, Gao Yang, Li Hong-Bo, Jiang Zu-Jun, Tan Huo, Lin Jing-Ren, Du Xin, Weng Jian-Yu, Nie Da-Nian, Lin Dong-Jun, Zhang Xiang-Zhong, Liu Qi-Fa, Xu Duo-Rong, Chen Hai-Jia, Ge Xiao-Hu, Wang Xiao-Yan, Xiao Yang. Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells Expanded In Vitro for Treatment of Aplastic Anemia: A Multicenter Phase II Trial. STEM CELLS Translational Medicine. 2017-may;:1569-1575. View Article Google Scholar
  9. Bhasin Ashu, Srivastava MVPadma, Kumaran SSenthil, Mohanty Sujata, Bhatia Rohit, Bose Sushmita, Gaikwad Shailesh, Garg Ajay, Airan Balram. Autologous Mesenchymal Stem Cells in Chronic Stroke. Cerebrovascular Diseases Extra. 2011;:93-104. View Article Google Scholar
  10. Park Yong-Beom, Ha Chul-Won, Lee Choong-Hee, Yoon YoungCheol, Park Yong-Geun. Cartilage Regeneration in Osteoarthritic Patients by a Composite of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells and Hyaluronate Hydrogel: Results from a Clinical Trial for Safety and Proof-of-Concept with 7 Years of Extended Follow-Up. STEM CELLS Translational Medicine. 2016-sep;:613-621. View Article Google Scholar

Downloads

Download data is not yet available.


Author's Affiliation
Article Details

Issue: Vol 4 No 3-4 (2017)
Page No.: 227-228
Published: Dec 29, 2017
Section: Letter to Editor
DOI: https://doi.org/10.15419/psc.v4i3-4.398

 Copyright Info

Creative Commons License

Copyright: The Authors. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 How to Cite
Salval, V., & Moto, Y. (2017). Expanded mesenchymal stem cell transplantation is safe in both local injection and vein transfusion. Progress in Stem Cell, 4(3-4), 227-228. https://doi.org/https://doi.org/10.15419/psc.v4i3-4.398

 Cited by

Article level Metrics by Paperbuzz/Impactstory
Article level Metrics by Altmetrics

 Article Statistics
HTML = 76 times
Download PDF   = 4 times
View Article   = 0 times
Total   = 4 times